As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
6 Analysts have issued a Anebulo Pharmaceuticals Inc forecast:
6 Analysts have issued a Anebulo Pharmaceuticals Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -9.22 -9.22 |
11%
11%
|
|
| Net Profit | -8.48 -8.48 |
3%
3%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Lawyer Joseph F on April 23, 2020 and is headquartered in Lakeway, TX.
| Head office | United States |
| CEO | Richard Cunningham |
| Employees | 3 |
| Founded | 2020 |
| Website | www.anebulo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


